HOWL - Werewolf Therapeutics GAAP EPS of -$0.56 beats by $0.05

Werewolf Therapeutics press release (NASDAQ:HOWL): Q1 GAAP EPS of -$0.56 beats by $0.05. The company expects that its existing cash and cash equivalents of $143.7M, together with the upfront payment from the Jazz agreement as well as access to the $20M first tranche of its term loan agreement with PWB, will be sufficient to enable the funding of its operating expenses and capital expenditure requirements through at least the fourth quarter of 2023.

For further details see:

Werewolf Therapeutics GAAP EPS of -$0.56 beats by $0.05